Special Issue

Circulating Factors—CAMLs, CTC/cfDNA—Predictive Factors to Aid in Diagnoses of Cancer and Determination of Its Recurrence

Message from the Guest Editor

Evaluable biological specimens within circulation can aid in diagnosing the presence, progression or steady state of a malignancy and are fundamental in determining whether a cancer treatment is effective. Circulating cells and liquid components that are indicators of the presence of a malignancy have been identified in blood. Cellular components include cancer-associated macrophage-like cells (CAMLs). CAMLs are enlarged phagocytic macrophage-like cells. A second cell is an intact circulating tumor cell (CTC). CTC testing is currently approved as a clinical test for breast, prostate and colorectal cancers. In addition to these cells, cell-free DNA is a blood component resulting both from normal and malignant cells. Cell-free DNA requires a base concentration to be detected and be able to differentiate tumor from normal DNA. All three of these biological entities are capable of being informative regarding the status of a tumor. Combining CAML, CTC and cfDNA analyses as a strategy for screening high-risk populations has the potential to identify and treat patients in early stage disease, where it can have the greatest impact.

Guest Editor

Dr. Katherine Alpaugh

Fox Chase Cancer Center, Philadelphia, PA 19111, USA

Deadline for manuscript submissions

closed (30 November 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/110961

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).